News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novartis AG (NVS) Release: First Myelofibrosis Medication For Life-Threatening Blood Cancer Approved In Singapore


5/30/2014 9:55:08 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Singapore, May 15, 2014 - (ACN Newswire) - Novartis announced today, the launch of Jakavi, the first and only approved oral medication to treat patients suffering from myelofibrosis in Singapore, and across more than 50 countries. Jakavi(R) (INC 424, ruxolitinib) is a JAK 1 and JAK 2 inhibitor for the treatment of disease-related splenomegaly and/or symptoms in adult patients with myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES